Artivion lowers 2026 guidance as Q1 revenue rises 18%; exercises Endospan option
Artivion reported first-quarter 2026 revenue of $116.3 million, up 18% on a GAAP basis from a year earlier, and net income of $1.4 million, or $0.03 per diluted share, compared with a net loss of $0.5 million a year earlier. The company lowered its full-year 2026 revenue and adjusted EBITDA guidance and said it has exercised its option to acquire Endospan, with an expected net purchase price of about $135.0 million to be funded by term loan borrowings and expected to close in the second quarter of 2026.
Key points
- Q1 2026 revenue $116.3 million, up 18% GAAP and 12% constant currency; net income $1.4 million, or $0.03 per diluted share
- 2026 revenue guidance cut to $480 million to $496 million from $486 million to $504 million
- 2026 adjusted EBITDA guidance cut to $100 million to $107 million from $105 million to $110 million
- Endospan option exercised May 7, 2026; base price $175.0 million, expected net price about $135.0 million, plus up to $200.0 million contingent consideration
The filing
Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.